Pacific Research Institute
Recent News About Pacific Research Institute
-
162 California biopharma companies could be negatively impacted by Inflation Reduction Act drug provision
A provision of the “Inflation Reduction Act” (IRA) could threaten investments in and by 162 California biopharma companies involved in what’s called “Small Molecule” drug development.
-
Finance research analyst: The shift to ESG and market influence is ‘all about control’
Paul Tice, a writer, analyst, and adjunct professor, suggests that the rise of ESG investing reflects a shift towards exerting control over capital flows and implementing government-directed agendas, diverging from traditional profit-maximizing approaches in finance. Tice was a guest on a recent episode of the Next Round Podcast.
-
Finance research analyst: ‘ESG is just the latest, shiniest object’ amidst evolving market trends and regulatory concerns
Paul Tice, a writer, analyst, and adjunct professor, suggests that the prolonged stability in the market until 2020 led to a continuous search for new trends, with ESG becoming the latest focus amid Wall Street's shift towards a less innovative and more compliant approach. Tice was a guest on a recent episode of Next Round Podcast.
-
Finance research analyst: The UN has ‘no place giving investment advice’
Paul Tice, writer, analyst, and adjunct professor, asserts that the UN's aspiration to offer investment advice exposes a significant strategic drift due to its lack of financial expertise, highlighting a broader trend of pursuing control over the financial market. Tice was a guest on a recent episode of Next Round Podcast.
-
Health Policy Analyst: Biden’s proposed expanded drug negotiations would lessen ‘our ability to fund R and D for future cures’
Sally Pipes, president of the Pacific Research Institute (PRI), said that the expanded Medicare drug price negotiations proposed by President Biden in his State of the Union address would be “detrimental” to research and development for “future cures.”